JP4467885B2 - タキサン誘導体を含有する抗腫瘍組成物 - Google Patents
タキサン誘導体を含有する抗腫瘍組成物 Download PDFInfo
- Publication number
- JP4467885B2 JP4467885B2 JP2002572997A JP2002572997A JP4467885B2 JP 4467885 B2 JP4467885 B2 JP 4467885B2 JP 2002572997 A JP2002572997 A JP 2002572997A JP 2002572997 A JP2002572997 A JP 2002572997A JP 4467885 B2 JP4467885 B2 JP 4467885B2
- Authority
- JP
- Japan
- Prior art keywords
- combination
- taxotere
- administered
- tumor
- antitumor agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Description
log10死滅細胞数=T−C(日)/3.32×Td
{式中、T−Cは細胞増殖にかかる時間を表し、これは所定の値(例えば1g)に達するのにかかる処理群(T)の腫瘍についての平均日数と処理群(C)の腫瘍についての平均日数であり、Tdは対照動物において腫瘍体積が二倍となるのに要する日数を表す}
に従って求められるlog10死滅細胞数によって定量することができる[T. H. Corbett et al., Cancer, 40,2660-2680 (1977); F. M. Schabel et al., Cancer Drug Development, Part B, Methods in Cancer Research, 17,3-51, New York, Academic Press Inc. (1979)]。log10死滅細胞数が0.7以上であればその製剤は活性があるとみなせる。log10死滅細胞数が2.8を超えればその製剤は極めて活性があるとみなせる。
Claims (7)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/813,018 US6441026B1 (en) | 1993-11-08 | 2001-03-21 | Antitumor compositions containing taxane derivatives |
PCT/IB2002/000853 WO2002074289A2 (en) | 2001-03-21 | 2002-03-21 | Antitumor compositions containing taxane derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004536790A JP2004536790A (ja) | 2004-12-09 |
JP2004536790A5 JP2004536790A5 (ja) | 2005-12-22 |
JP4467885B2 true JP4467885B2 (ja) | 2010-05-26 |
Family
ID=25211230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002572997A Expired - Lifetime JP4467885B2 (ja) | 2001-03-21 | 2002-03-21 | タキサン誘導体を含有する抗腫瘍組成物 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6441026B1 (ja) |
EP (1) | EP1478355B1 (ja) |
JP (1) | JP4467885B2 (ja) |
CN (2) | CN1536995A (ja) |
AT (1) | ATE355837T1 (ja) |
AU (1) | AU2002244877B2 (ja) |
BR (1) | BR0208274A (ja) |
CA (1) | CA2440160C (ja) |
CY (1) | CY1106582T1 (ja) |
DE (1) | DE60218751T2 (ja) |
DK (1) | DK1478355T3 (ja) |
EA (1) | EA006878B1 (ja) |
ES (1) | ES2282400T3 (ja) |
HU (1) | HUP0500478A2 (ja) |
IL (1) | IL157992A (ja) |
MX (1) | MXPA03008539A (ja) |
PT (1) | PT1478355E (ja) |
SI (1) | SI1478355T1 (ja) |
WO (2) | WO2002074232A2 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
JP2004529904A (ja) * | 2001-03-14 | 2004-09-30 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ |
ITRM20020191A1 (it) * | 2002-04-08 | 2003-10-08 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att |
CN1652845A (zh) * | 2002-05-17 | 2005-08-10 | 安万特医药股份有限公司 | 多西他赛/阿霉素/环磷酰胺在辅助治疗乳腺癌和卵巢癌中的用途 |
AU2003287081A1 (en) * | 2002-10-16 | 2004-05-04 | Ilex Products, Inc. | Clofarabine and taxane chemotherapy combination |
ITMI20030317A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale. |
CA2526278A1 (en) * | 2003-05-20 | 2004-12-02 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
CN100340296C (zh) * | 2005-02-03 | 2007-10-03 | 山东蓝金生物工程有限公司 | 一种抗癌体内植入剂 |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
KR101914254B1 (ko) | 2005-02-18 | 2018-11-02 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
ATE432955T1 (de) * | 2005-12-05 | 2009-06-15 | Nitto Denko Corp | Polyglutamat-aminosäure-konjugate und verfahren |
EP1913958B1 (en) * | 2006-08-03 | 2009-12-23 | Sanofi-Aventis | Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
WO2008124735A2 (en) * | 2007-04-10 | 2008-10-16 | Nitto Denko Corporation | Multi-functional polyglutamate drug carriers |
CN101707869A (zh) * | 2007-05-09 | 2010-05-12 | 日东电工株式会社 | 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物 |
DK2155255T3 (da) | 2007-05-09 | 2013-09-02 | Nitto Denko Corp | Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat |
EP2155254B1 (en) * | 2007-05-09 | 2012-11-28 | Nitto Denko Corporation | Polymers conjugated with platinum drugs |
RU2010137032A (ru) * | 2008-03-06 | 2012-04-20 | Нитто Денко Корпорейшн (Jp) | Конъюгаты паклитаксела с полимером и способы лечения рака |
DK2552415T3 (en) | 2010-03-29 | 2016-11-28 | Abraxis Bioscience Llc | Methods for treating cancer |
MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
CN103140225A (zh) | 2010-06-04 | 2013-06-05 | 阿布拉科斯生物科学有限公司 | 治疗胰腺癌的方法 |
EP2638395A4 (en) * | 2010-11-12 | 2016-06-01 | Endocyte Inc | METHOD FOR TREATING CARCINOMA |
CN102241648B (zh) * | 2011-01-31 | 2016-08-03 | 沈阳东星医药科技有限公司 | 抗多药耐药紫杉烷类衍生物及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
US4876399A (en) | 1987-11-02 | 1989-10-24 | Research Corporation Technologies, Inc. | Taxols, their preparation and intermediates thereof |
US5136060A (en) | 1989-11-14 | 1992-08-04 | Florida State University | Method for preparation of taxol using an oxazinone |
US5015744A (en) | 1989-11-14 | 1991-05-14 | Florida State University | Method for preparation of taxol using an oxazinone |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5645988A (en) | 1991-05-08 | 1997-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of identifying drugs with selective effects against cancer cells |
AU2005692A (en) | 1991-05-08 | 1992-12-21 | United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer |
US5284864A (en) | 1991-09-23 | 1994-02-08 | Florida State University | Butenyl substituted taxanes and pharmaceutical compositions containing them |
US5229526A (en) | 1991-09-23 | 1993-07-20 | Florida State University | Metal alkoxides |
US5262409A (en) | 1991-10-11 | 1993-11-16 | Fred Hutchinson Cancer Research Center | Binary tumor therapy |
US5294737A (en) | 1992-02-27 | 1994-03-15 | The Research Foundation State University Of New York | Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
EP0982028A1 (en) * | 1998-08-20 | 2000-03-01 | Aventis Pharma S.A. | New use of taxoid derivatives |
-
2001
- 2001-03-21 US US09/813,018 patent/US6441026B1/en not_active Expired - Fee Related
-
2002
- 2002-03-21 HU HU0500478A patent/HUP0500478A2/hu unknown
- 2002-03-21 ES ES02713093T patent/ES2282400T3/es not_active Expired - Lifetime
- 2002-03-21 CA CA2440160A patent/CA2440160C/en not_active Expired - Lifetime
- 2002-03-21 AU AU2002244877A patent/AU2002244877B2/en not_active Ceased
- 2002-03-21 WO PCT/IB2002/002239 patent/WO2002074232A2/en not_active Application Discontinuation
- 2002-03-21 DE DE60218751T patent/DE60218751T2/de not_active Expired - Lifetime
- 2002-03-21 AT AT02713093T patent/ATE355837T1/de active
- 2002-03-21 MX MXPA03008539A patent/MXPA03008539A/es active IP Right Grant
- 2002-03-21 BR BR0208274-8A patent/BR0208274A/pt not_active IP Right Cessation
- 2002-03-21 PT PT02713093T patent/PT1478355E/pt unknown
- 2002-03-21 JP JP2002572997A patent/JP4467885B2/ja not_active Expired - Lifetime
- 2002-03-21 SI SI200230525T patent/SI1478355T1/sl unknown
- 2002-03-21 CN CNA028068572A patent/CN1536995A/zh active Pending
- 2002-03-21 CN CNA2009101299448A patent/CN101590057A/zh active Pending
- 2002-03-21 DK DK02713093T patent/DK1478355T3/da active
- 2002-03-21 EP EP02713093A patent/EP1478355B1/en not_active Expired - Lifetime
- 2002-03-21 WO PCT/IB2002/000853 patent/WO2002074289A2/en active IP Right Grant
- 2002-03-21 EA EA200301047A patent/EA006878B1/ru not_active IP Right Cessation
-
2003
- 2003-09-18 IL IL157992A patent/IL157992A/en not_active IP Right Cessation
-
2007
- 2007-05-10 CY CY20071100643T patent/CY1106582T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL157992A (en) | 2008-08-07 |
EP1478355A2 (en) | 2004-11-24 |
DE60218751D1 (de) | 2007-04-19 |
ATE355837T1 (de) | 2007-03-15 |
WO2002074289A2 (en) | 2002-09-26 |
PT1478355E (pt) | 2007-05-31 |
US20020031505A1 (en) | 2002-03-14 |
JP2004536790A (ja) | 2004-12-09 |
MXPA03008539A (es) | 2004-08-11 |
HUP0500478A2 (hu) | 2005-08-29 |
DK1478355T3 (da) | 2007-07-02 |
EA006878B1 (ru) | 2006-04-28 |
CN1536995A (zh) | 2004-10-13 |
EP1478355B1 (en) | 2007-03-07 |
US6441026B1 (en) | 2002-08-27 |
DE60218751T2 (de) | 2007-11-22 |
AU2002244877B2 (en) | 2006-07-20 |
EA200301047A1 (ru) | 2004-06-24 |
CN101590057A (zh) | 2009-12-02 |
BR0208274A (pt) | 2004-07-13 |
SI1478355T1 (sl) | 2007-08-31 |
WO2002074232A2 (en) | 2002-09-26 |
CY1106582T1 (el) | 2012-01-25 |
WO2002074289A3 (en) | 2004-09-02 |
ES2282400T3 (es) | 2007-10-16 |
CA2440160A1 (en) | 2002-09-26 |
CA2440160C (en) | 2011-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4467885B2 (ja) | タキサン誘導体を含有する抗腫瘍組成物 | |
KR100334051B1 (ko) | 탁산유도체를함유하는항종양조성물 | |
EP1827437B1 (en) | Combinations of therapeutic agents for treating cancer | |
AU2002244877A1 (en) | Antitumor compositions containing taxane derivatives | |
AU758191B2 (en) | Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate | |
US20030087839A1 (en) | Combined preparations comprising morpholine anthracyclines and anticancer agent | |
JP2007511509A (ja) | Et−743およびパクリタキセルの使用を含むガンの併用療法 | |
Saotome et al. | Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma | |
Kelly | Irinotecan in small-cell lung cancer: current data | |
de Dycker et al. | Sequential proleukin (rIL-2) by continuous infusion with cisplatin and cyclophosphamide in patients with unresectable ovarian cancer | |
JPH06116164A (ja) | 癌の併用化学療法剤 | |
Tognoni et al. | A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041130 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20041130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041130 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20041202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080708 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081007 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081008 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081016 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090602 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090803 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090915 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091215 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100216 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100224 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130305 Year of fee payment: 3 |